A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With alpha-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan.
Phase of Trial: Phase II/III
Latest Information Update: 20 May 2016
At a glance
- Drugs Alogliptin (Primary) ; Voglibose
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda
- 10 Jun 2017 Biomarkers information updated
- 17 Dec 2010 New source identified and integrated (ClinicalTrials.gov, NCT01263483).
- 17 Dec 2010 Actual initiation date (Jan 2007) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History